Hepatitis C Therapeutic Pipeline Discussed in New Global Markets Direct Study Published at MarketPublishers.com
Hepatitis C, an infection caused by the hepatitis C virus (HCV), afflicts over 180 million people from pole to pole. Acute hepatitis C moves to the chronic stage in about 80% of cases, with the resultant risk of progressive liver fibrosis, cirrhosis and hepatocellular carcinoma.
Typical hepatitis C treatment with pegylated interferon (PEG-IFN) in association with ribavirin (RBV) leads to a sustained virological response (SVR) in around 50%–60% of people with chronic hepatitis C. However, treatment uptake remains low, due to toxicity of interferon-based therapy, prolonged course of treatment, social marginalisation of many people with chronic HCV infection, shortage of treatment infrastructure, and lack of awareness of the curative potential of treatment. The fast-paced development of direct-acting antiviral drug regimens for the disease has instilled hope that therapeutic treatment is on the road of becoming more efficient as well as taking less time.
New research study “Hepatitis C – Pipeline Review, H1 2013” elaborated by Global Markets Direct provides an in-depth overview of the global therapeutic scenario for hepatitis C.
The report reviews the hepatitis C products under development by companies and different research organizations; examines the products being in various phases of development – from discovery till registration; features pipeline projects on the basis of monotherapy and combined therapeutics; analyzes the hepatitis C pipeline in terms of route of administration and molecule type; uncovers the discontinued projects, besides looking into the factors that drove them from pipeline. Furthermore, the top companies involved in the therapeutic development for hepatitis C are identified, as well as the latest news and deals relating to the products are addressed in the research as well.
Title: Hepatitis C – Pipeline Review, H1 2013
Published: February, 2013
Price: US$ 2,500.00
More Pipeline Reviews H1 2013 by Global Markets Direct Include:
- Melanoma – Pipeline Review, H1 2013
- Non-Small Cell Lung Cancer – Pipeline Review, H1 2013
- Bladder Cancer – Pipeline Review, H1 2013
- Bone Disorders – Pipeline Review, H1 2013
- HIV / AIDS – Pipeline Review, H1 2013
More new research studies by Global Markets Direct can be found at http://marketpublishers.com/members/globalmarketsdir/info.html